Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2025 13:07 ET | Source: Aptose Biosciences, Inc.

Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

Aptose Selected for Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at EHA2025
May 08, 2025 07:00 ET | Source: Aptose Biosciences, Inc.

Aptose Reports First Quarter 2025 Results

Aptose Reports First Quarter 2025 Results; Highlights Progress in TUSCANY Clinical Trial of Tuspetinib in AML Triple Frontline Therapy
May 05, 2025 07:00 ET | Source: Aptose Biosciences, Inc.

Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial

Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial
April 23, 2025 17:00 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Auditor Not Standing for Re-Appointment

Aptose Announces Auditor Not Standing for Re-Appointment
April 23, 2025 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference

Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
April 01, 2025 08:30 ET | Source: Aptose Biosciences, Inc.

Aptose Common Shares to Delist from Nasdaq as of April 2, 2025

Nasdaq to Delist Aptose Common Shares as of April 2, 2025
March 28, 2025 08:01 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Year End 2024 Results and Corporate Highlights

Aptose Reports Year End 2024 Results and Corporate Highlights
March 17, 2025 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
February 20, 2025 07:32 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort

Aptose Announces Positive Clinical Safety Review and Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib
February 18, 2025 16:30 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Reverse Share Split

Aptose Announces Reverse Share Split

Next Page keyboard_arrow_right